[Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant]
- PMID: 20055140
[Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant]
Abstract
The present study is to establish the population pharmacokinetic (PPK) model of tacrolimus and to estimate PPK parameters of tacrolimus for the individualization of tacrolimus administration in patients with hematopoietic stem cell transplant. A total of 671 blood samples were collected from 68 hematopoietic stem cell transplant patients and clinical data were retrospectively collected from the medical records of these patients. Population pharmacokinetical analysis was performed using the nonlinear mixed-effect model (NONMEM) program. The Bootstrap and data splitting were used simultaneously to validate the final population pharmacokinetical models. The basic structural model was best described as one-compartment pharmacokinetical model with first-order absorption and elimination. A number of covariates including demographic characteristic, biochemical and hematological index, combined drugs, inter-occasion variability (IOV) and other variables, e.g. primary disease, post operation days (POD), the type of transplantation and the sources of donor, were screened for their influence on the pharmacokinetic parameters of tacrolimus. The population typical values of tacrolimus CL, V, F were 12.1 L x h(-1), 686 L, 42.2%; and the inter-individual variability of these parameters were 23.5%, 96.4%, 43.8%, respectively. The absorption rate constant was fixed 4.3 h(-1). The residual error between observed and model- predicted concentration was 3.03 ng x mL(-1). The CYP enzyme inhibitor (INHI), POD and age were identified to be the main covariates that influence tacrolimus CL, and hemoglobulin (HGB) was the main covariate that may explain the variability in tacrolimus V. The IOV of CL, V, F were 22.2%, 6.23%, 30.3%, respectively. The population pharmacokinetic data obtained in the present study have significant clinical value for the individualization of tacrolimus therapy in hematopoietic stem cell transplant patients.
Similar articles
-
Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.Eur J Clin Pharmacol. 2002 Dec;58(9):597-605. doi: 10.1007/s00228-002-0517-7. Epub 2002 Nov 15. Eur J Clin Pharmacol. 2002. PMID: 12483452
-
Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.Bone Marrow Transplant. 2001 Oct;28(8):753-8. doi: 10.1038/sj.bmt.1703224. Bone Marrow Transplant. 2001. PMID: 11781626
-
The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients.Ther Drug Monit. 2012 Apr;34(2):126-33. doi: 10.1097/FTD.0b013e31824a67eb. Ther Drug Monit. 2012. PMID: 22377746
-
Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach.Br J Clin Pharmacol. 2019 Dec;85(12):2793-2823. doi: 10.1111/bcp.14110. Epub 2019 Dec 17. Br J Clin Pharmacol. 2019. PMID: 31471970 Free PMC article.
-
A Comprehensive Mixed-Method Approach to Characterize the Source of Diurnal Tacrolimus Exposure Variability in Children: Systematic Review, Meta-analysis, and Application to an Existing Data Set.J Clin Pharmacol. 2024 Mar;64(3):334-344. doi: 10.1002/jcph.2352. Epub 2023 Oct 10. J Clin Pharmacol. 2024. PMID: 37740566
Cited by
-
Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients.Front Pharmacol. 2022 Jul 6;13:891648. doi: 10.3389/fphar.2022.891648. eCollection 2022. Front Pharmacol. 2022. PMID: 35873585 Free PMC article.